1. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. (22nd March 2020) Authors: Asselah, Tarik; Pol, Stanislas; Hezode, Christophe; Loustaud‐Ratti, Veronique; Leroy, Vincent; Ahmed, Si Nafa Si; Ozenne, Violaine; Bronowicki, Jean‐Pierre; Larrey, Dominique; Tran, Albert; Alric, Laurent; Nguyen‐Khac, Eric; Robertson, Michael N.; Hanna, George J.; Brown, Deborah; Asante‐Appiah, ... Journal: Liver international Issue: Volume 40:Number 5(2020) Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results. (December 2014) Authors: Jensen, Donald M.; Sherman, Kenneth; Hezode, Christophe; Pol, Stanislas; Zeuzem, Stefan; De Ledinghen, Victor; Tran, Albert; Elkhashab, Magdy; Younes, Ziad H; Kugelmas, Marcelo; Mauss, Stefan; Everson, Gregory T.; Luketic, Velimir; Vierling, John; Serfaty, Lawrence; Brunetto, Maurizia; Heo, Jeong... Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Issue 10 (13th November 2015) Authors: Saadoun, David; Thibault, Vincent; Si Ahmed, Si Nafa; Alric, Laurent; Mallet, Maxime; Guillaud, Constance; Izzedine, Hassane; Plaisier, Aurélie; Fontaine, Hélène; Costopoulos, Myrto; Le Garff-Tavernier, Magali; Hezode, Christophe; Pol, Stanislas; Musset, Lucile; Poynard, Thierry; Cacoub, Patrice Journal: Annals of the rheumatic diseases Issue: Volume 75:Issue 10(2016) Page Start: 1777 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10215 (14th December 2019) Authors: Younossi, Zobair M; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N; Sheridan, David; Sheikh, Muhammad Y; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F; Kowdley, Kris V;... Journal: Lancet Issue: Volume 394:Issue 10215(2019) Page Start: 2184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10215 (14th December 2019) Authors: Younossi, Zobair M; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N; Sheridan, David; Sheikh, Muhammad Y; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F; Kowdley, Kris V;... Journal: Lancet Issue: Volume 394:Issue 10215(2019) Page Start: 2184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. (March 2017) Authors: Bourlière, Marc; Rabiega, Pascaline; Ganne-Carrie, Nathalie; Serfaty, Lawrence; Marcellin, Patrick; Barthe, Yoann; Thabut, Dominique; Guyader, Dominique; Hezode, Christophe; Picon, Magali; Causse, Xavier; Leroy, Vincent; Bronowicki, Jean Pierre; Carrieri, Patrizia; Riachi, Ghassan; Rosa, Isabelle... Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 3(2017) Page Start: 177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+). Issue 5 (4th March 2016) Authors: Leroy, Vincent; Angus, Peter; Bronowicki, Jean‐Pierre; Dore, Gregory J.; Hezode, Christophe; Pianko, Stephen; Pol, Stanislas; Stuart, Katherine; Tse, Edmund; McPhee, Fiona; Bhore, Rafia; Jimenez‐Exposito, Maria Jesus; Thompson, Alexander J. Journal: Hepatology Issue: Volume 63:Issue 5(2016:May) Page Start: 1430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗